Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels

Neurobiology of Disease

Volumn 40, Issue 1, 2010, Pages 340-347

  Timmer, Nienke M ^a   van Dijk, Laura ^a   der Zee, Catharina E E M van ^a   Kiliaan, Amanda ^a   de Waal, Robert M W ^b   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Amyloid ; Enoxaparin; Transgenic mice; Treatment

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ENOXAPARIN; GUANIDINE; SODIUM CHLORIDE;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN AGGREGATION; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ENOXAPARIN; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID;

EID: 77955844393     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.06.008     Document Type: Article

References (36)

1. Balemans M.C., Huibers M.M., Eikelenboom N.W., Kuipers A.J., van Summeren R.C., Pijpers M.M., Tachibana M., Shinkai Y., van B.H., Van der Zee C.E. Reduced exploration, increased anxiety, and altered social behavior: autistic-like features of euchromatin histone methyltransferase 1 heterozygous knockout mice. Behav. Brain Res. 2009.
2. Bergamaschini L., Rossi E., Storini C., Pizzimenti S., Distaso M., Perego C., De L.A., Vergani C., De Simoni M.G. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci. 2004, 24:4181-4186.
3. Bergamaschini L., Rossi E., Vergani C., De Simoni M.G. Alzheimer's disease: another target for heparin therapy. Sci. World J. 2009, 9:891-908.
4. Davis J., Van Nostrand W.E. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Proc. Natl Acad. Sci. USA 1996, 93:2996-3000.
5. Davis J., Xu F., Deane R., Romanov G., Previti M.L., Zeigler K., Zlokovic B.V., Van Nostrand W.E. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 2004, 279:20296-20306.
6. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 2001, 98:8850-8855.
7. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006.
8. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
9. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
10. Hooijmans C.R., Van der Zee C.E., Dederen P.J., Brouwer K.M., Reijmer Y.D., van Groen T, Broersen L.M., Lutjohann D., Heerschap A., Kiliaan A.J. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol. Dis. 2009, 33:482-498.
11. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001, 17:157-165.
12. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
13. Kelly P.H., Bondolfi L., Hunziker D., Schlecht H.P., Carver K., Maguire E., Abramowski D., Wiederhold K.H., Sturchler-Pierrat C., Jucker M., Bergmann R., Staufenbiel M., Sommer B. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol. Aging 2003, 24:365-378.
14. Kisilevsky R., Lemieux L.J., Fraser P.E., Kong X., Hultin P.G., Szarek W.A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1995, 1:143-148.
15. Klein W.L., Krafft G.A., Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 2001, 24:219-224.
16. Lalonde R., Kim H.D., Fukuchi K. Exploratory activity, anxiety, and motor coordination in bigenic APPswe+PS1/DeltaE9 mice. Neurosci. Lett. 2004, 369:156-161.
17. Lalonde R., Kim H.D., Maxwell J.A., Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci. Lett. 2005, 390:87-92.
18. Lalonde R., Strazielle C. Exploratory activity and motor coordination in old versus middle-aged C57BL/6J mice. Arch. Gerontol. Geriatr. 2009, 49:39-42.
19. Leveugle B., Ding W., Laurence F., Dehouck M.P., Scanameo A., Cecchelli R., Fillit H. Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J. Neurochem. 1998, 70:736-744.
20. Lipp H.P., Wolfer D.P. Genetically modified mice and cognition. Curr. Opin. Neurobiol. 1998, 8:272-280.
21. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 2003, 23:29-33.
22. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
23. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D., St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12:801-808.
24. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
25. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
26. Puzzo D., Staniszewski A., Deng S.X., Privitera L., Leznik E., Liu S., Zhang H., Feng Y., Palmeri A., Landry D.W., Arancio O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J. Neurosci. 2009, 29:8075-8086.
27. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
28. Timmer N.M., Schirris T.J., Bruinsma I.B., Otte-Holler I., van Kuppevelt T.H., de Waal R.M., Verbeek M.M. Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Abeta40 (DAbeta(1-40)) are modulated by sulfate moieties of heparin. Neurosci. Res. 2009.
29. Ujiie M., Dickstein D.L., Carlow D.A., Jefferies W.A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003, 10:463-470.
30. van Horssen J., Kleinnijenhuis J., Maass C.N., Rensink A.A., Otte-Holler I., David G., van den Heuvel L.P., Wesseling P., de Waal R.M., Verbeek M.M. Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol. Aging 2002, 23:537-545.
31. van Horssen J., Otte-Holler I., David G., Maat-Schieman M.L., van den Heuvel L.P., Wesseling P., de Waal R.M., Verbeek M.M. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. (Berl) 2001, 102:604-614.
32. van Horssen J., Wesseling P., van den Heuvel L.P., de Waal R.M., Verbeek M.M. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2003, 2:482-492.
33. van Groen T., Kiliaan A.J., Kadish I. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol. Dis. 2006, 23:653-662.
34. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 2002, 30:552-557.
35. Wilhelmus M.M., Otte-Holler I., Wesseling P., de Waal R.M., Boelens W.C., Verbeek M.M. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathol. Appl. Neurobiol. 2006, 32:119-130.
36. Zhu H., Yu J., Kindy M.S. Inhibition of amyloidosis using low-molecular-weight heparins. Mol. Med. 2001, 7:517-522.